Document:

EX-10.1

 Exhibit 10.1 

ACHILLION PHARMACEUTICALS, INC. 

Nonstatutory Stock Option Agreement 

Inducement Grant Pursuant to NASDAQ Stock Market Rule 5635(c)(4) 

1. Grant of Option. This agreement (the “Agreement”) evidences the grant by Achillion Pharmaceuticals, Inc. (the
“Company”) on [                    ], 2017 (the “Grant Date”) to
[                    ], an employee of the Company (the “Participant”), of an option (the “Option”) to purchase, on the
terms provided herein, a total of [                ] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (“Common
Stock”) at $[                ] per Share, in connection with the commencement of the Participant’s employment with the Company. Unless earlier
terminated, this Option shall expire at 5:00 p.m., Eastern Time, on [Ten Years minus 1 Day from Grant Date] (the “Option Expiration Date”). Except as otherwise indicated by the context, the term “Participant”, as used
herein, shall be deemed to include any person who acquires the right to exercise the Option validly under its terms. 
 2. Inducement
Grant. The Option was granted to the Participant pursuant to the inducement grant exception under NASDAQ Stock Market Rule 5635(c)(4), and not pursuant to the Company’s 2015 Stock Incentive Plan (the “Plan”) or any equity
incentive plan of the Company, as an inducement that is material to the Participant’s employment with the Company. 
 3. Nonstatutory
Option. It is intended that the Option shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). 

4. Vesting Schedule. 
 (a)
Except as otherwise provided herein, this Option will become exercisable (“vest”) as to 25% of the original number of Shares on the first anniversary of the Grant Date and as to an additional 6.25% of the original number of Shares at the
end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date. 

(b) The right of exercise shall be cumulative so that to the extent the Option is not exercised in any period to the maximum extent permissible
it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Option Expiration Date or the termination of the Option under Section 5 hereof. 

5. Exercise of Option. 

(a) Form of Exercise. Each election to exercise the Option shall be in writing (which may be in electronic form), signed by the
Participant, and accompanied by payment in full pursuant to Section 6 hereof. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of the Option may be for any fractional share.
Subject to the conditions in this Agreement, Common Stock purchased upon the exercise of this Option will be delivered as soon as practicable following exercise. 

 (b) Continuous Relationship with the Company Required. Except as otherwise provided in
this Section 5, the Option may not be exercised unless the Participant, at the time he or she exercises the Option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to,
(i) the Company or (ii) any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an “Eligible Participant”). 

(c) Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except
as provided in paragraphs (d), (e) and (f) below, the right to exercise the Option shall terminate three months after such cessation (but in no event after the Option Expiration Date), provided that the Option shall be exercisable only
to the extent that the Participant was entitled to exercise the Option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Option Expiration Date, violates the
non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise the
Option shall terminate immediately upon such violation. 
 (d) Exercise Period Upon Death or Disability. If the Participant dies or
becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Option Expiration Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in
paragraph (e) below, the Option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that the
Option shall be exercisable only to the extent that the Option was exercisable by the Participant on the date of his or her death or disability, and further provided that the Option shall not be exercisable after the Option Expiration Date. 

(e) Termination for Cause. If, prior to the Option Expiration Date, the Participant’s employment or other relationship with the
Company is terminated by the Company for Cause (as defined below), the right to exercise the Option shall terminate immediately upon the effective date of such termination of employment or other relationship. If, prior to the Option Expiration Date,
the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of the delivery of
such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant’s employment or other
relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding
sentence, terminate immediately upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting, advisory, non-disclosure, non-competition or other similar agreement that contains a definition of “cause” for termination of employment or other relationship, “Cause” shall have the meaning ascribed to such term in such
agreement. Otherwise, “Cause” shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any
provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the 

  
 - 2 - 

 
Company), as determined by the Company, which determination shall be conclusive. The Participant’s employment or other relationship shall be considered to have been terminated for
“Cause” if the Company determines, within 30 days after the Participant’s resignation, that termination for Cause was warranted. 

(f) Board Discretion. Notwithstanding this Section 5, the Board of Directors of the Company (the “Board”) may, in its
sole discretion, determine the effect on the Option of the Participant’s death, disability, termination or other cessation of employment, authorized leave of absence or other change in employment or other status of the Participant and the
extent to which, and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Option. For the purposes of this Agreement, a
“Designated Beneficiary” is (i) the beneficiary designated, in a manner determined by the Board, by the Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or
(ii) in the absence of an effective designation by the Participant, the Participant’s estate. 
 6. Methods of Payment Upon
Exercise. Common Stock purchased upon the exercise of this Option shall be paid for as follows: 
 (a) in cash or by check, payable to
the order of the Company; 
 (b) except as may otherwise be approved by the Board, in its sole discretion, by (i) delivery of an
irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of
irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(c) to the extent approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common
Stock owned by the Participant valued at their Fair Market Value (as determined by (or in a manner approved by) the Board), provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if
acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled
vesting or other similar requirements; 
 (d) to the extent approved by the Board, in its sole discretion, by delivery of a notice of
“net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares underlying the portion of the Option being exercised, less (ii) such number of shares as is equal to (A) the
aggregate exercise price for the portion of the Option being exercised divided by (B) the Fair Market Value on the date of exercise; 

(e) to the extent permitted by applicable law and approved by the Board, in its sole discretion, by payment of such other lawful consideration
as the Board may determine; or 
 (f) by any combination of the above permitted forms of payment. 

  
 - 3 - 

 7. Withholding. 

(a) General. No Shares will be issued pursuant to the exercise of the Option and the Company will not otherwise recognize any ownership
of Common Stock under the Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local or other income or employment tax withholding obligations required by
law to be withheld in respect of the Option. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant
must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. 

(b) Satisfaction of Obligations by Delivery of Shares. If approved by the Board, in its sole discretion, the Participant may satisfy
such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares retained from the Option creating the tax obligation, valued at their Fair Market Value; provided,
however, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum
statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture,
unfulfilled vesting or other similar requirements. 
 8. Nontransferability of Option. The Option may not be sold, assigned,
transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will, the laws of descent and distribution, or a qualified domestic relations order, and, during the lifetime of the Participant,
the Option shall be exercisable only by the Participant; provided, however, that, subject to the approval of the Board, the Participant may make a gratuitous transfer of this Option to or for the benefit of any immediate family member,
family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof so long as the Company is eligible to use a Form S-8 under the Securities Act for the
registration of the sale of the Common Stock subject to this Option to such proposed transferee; provided further, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted
transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of this Option. For
the avoidance of doubt, nothing contained in this Section 8 shall be deemed to restrict a transfer to the Company. 
 9. Adjustments
for Changes in Common Stock and Certain Other Events. 
 (a) Changes in Capitalization. In the event of any stock split, reverse
stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of
Common Stock other than an ordinary cash dividend, the number and class of securities and exercise price per share of this Option shall be equitably adjusted by the Company (or a substituted option may be made, if applicable) in the manner
determined by the Board. Without 

  
 - 4 - 

 
limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to
an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then the Participant who exercises this Option between the record date and the distribution date for such
stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close
of business on the record date for such stock dividend. 
 (b) Reorganization Events. 

(i) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or into another
entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common Stock of the
Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

(ii) Consequences of a Reorganization Event on this Option. 

(A) In connection with a Reorganization Event, the Board may take any one or more of the following actions as to this Option (or any portion
thereof) on such terms as the Board determines (except to the extent specifically provided otherwise in another agreement between the Company and the Participant): (i) provide that this Option shall be assumed, or a substantially equivalent Option
shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to the Participant, provide that all of the unexercised and/ or unvested portion of this Option will terminate immediately prior to
the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that this Option shall become exercisable, realizable,
or deliverable, or restrictions applicable to this Option shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive
upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to the Participant with respect to this Option equal to (A) the number of
shares of Common Stock subject to the vested portion of this Option (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the
Acquisition Price over (II) the exercise price of this Option and any applicable tax withholdings, in exchange for the termination of this Option, (v) provide that, in connection with a liquidation or dissolution of the Company, this
Option shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. 

(B) For purposes of Section 9(b)(ii)(A)(i), this Option shall be considered assumed if, following consummation of the Reorganization
Event, this Option confers the right to purchase, for each share of Common Stock subject to this Option immediately prior to the consummation of the Reorganization Event, the consideration (whether 

  
 - 5 - 

 
cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the
Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration
received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the
consideration to be received upon the exercise of this Option to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of
the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. 

10. Miscellaneous. 
 (a)
No Right To Employment or Other Status. The grant of this Option shall not be construed as giving the Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any
time to dismiss or otherwise terminate its relationship with the Participant free from any liability or claim hereunder. 
 (b) No Rights
As Stockholder. Subject to the provisions of this Option, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to this Option until becoming the
record holder of such shares. For the avoidance of doubt, this Option also does not provide for the payment or accrual of dividend equivalents. 

(c) Administration by Board. The Board will administer this Agreement and may construe and interpret the terms hereof. The Board may
correct any defect, supply any omission or reconcile any inconsistency in this Agreement in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in
the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in or under this Agreement. 

(d) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers hereunder to
one or more committees or subcommittees of the Board (a “Committee”). All references herein to the “Board” shall mean the Board or a Committee of the Board to the extent that the Board’s powers or authority hereunder have
been delegated to such Committee. 
 (e) Amendment. The Board may amend, modify or terminate this Agreement, including but not limited
to, substituting another option of the same or a different type and changing the date of exercise or realization. The Participant’s consent to such action shall be required unless (i) the Board determines that the action, taking into
account any related action, does not materially and adversely affect the Participant or (ii) the change is permitted under Section 9. 

  
 - 6 - 

 (f) Limitation on Repricing. Notwithstanding Section 10(e) above, unless such action
is approved by the Company’s stockholders, the Company may not (except as provided for under Section 9): (1) amend this Option to provide an exercise price per share that is lower than the then-current exercise price per share of the
Option, (2) cancel this Option and grant in substitution therefor a new option covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of this
Option, (3) cancel in exchange for a cash payment this Option if its exercise price per share is below the then-current Fair Market Value, other than pursuant to Section 9, or (4) take any other action with respect to this Option that
constitutes a “repricing” within the meaning of the rules of the NASDAQ Global Select Market. 
 (g) Conditions on Delivery of
Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to this Agreement until (i) all conditions of this Agreement have been met to the satisfaction of the Company, (ii) in the opinion of the
Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and
regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

(h) Acceleration. The Board may at any time provide that this Option shall become immediately exercisable in whole or in part, free of
some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 
 (i) Compliance with
Section 409A of the Code. Except as provided herein, if and to the extent any portion of any payment, compensation or other benefit provided to the Participant in connection with his or her employment termination is determined to constitute
“nonqualified deferred compensation” within the meaning of Section 409A of the Code and the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with
its procedures, by which determination the Participant (through accepting this Option) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after
the date of “separation from service” (as determined under Section 409A of the Code) (the “New Payment Date”), except as Section 409A of the Code may then permit. The aggregate of any payments that otherwise would have
been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original
schedule. The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits hereunder are determined to constitute nonqualified
deferred compensation subject to Section 409A of the Code but do not to satisfy the conditions of that section. 
 (j) Limitations on
Liability. Notwithstanding any other provisions of this Agreement, no individual acting as a director, officer, employee or agent of the Company will be liable to the Participant, a spouse, a beneficiary, or any other person for any claim, loss,
liability, or expense incurred in connection with this Agreement, nor will such individual be personally 

  
 - 7 - 

 
liable with respect to this Agreement because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company. The Company
will indemnify and hold harmless each director, officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of this Agreement has been or will be delegated, against any cost or expense
(including attorneys’ fees) or liability (including any sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning this Agreement unless arising out of such person’s own fraud or
bad faith. 
 (k) Severability. The invalidity or unenforceability of any provision hereof shall not affect the validity or
enforceability of any other provision hereof, and each such other provision shall be severable and enforceable to the extent permitted by law. 

(l) Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware. 

(m) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of
which together will constitute one in the same instrument. 
 (n) Entire Agreement. This Agreement constitutes the entire agreement
between the parties, and supersedes all prior agreements and understandings, relating to the subject matter hereof. 
 [Remainder of Page
Intentionally Left Blank] 

  
 - 8 - 

 The Company has caused this Option to be executed by its duly authorized officer. 

 

			
	 ACHILLION PHARMACEUTICALS,
INC.

 
			
		
	 By:
	 	 
	 Name:    
	 	 
	 Title:
	 	 

  
 Signature Page to
Inducement Grant 

 PARTICIPANT ACCEPTANCE 

The undersigned hereby accepts the foregoing Option and agrees to the terms and conditions thereof. 

 

			
	 PARTICIPANT

		
	 By:
	 	 
	 Name:
	 	 
	 Address:
	 	 
		 	 
		 	 
	 Telephone:
	 	 

  
 Signature Page to
Inducement GrantEX-10.2

 Exhibit 10.2 

AMENDMENT NO. 5 TO LEASE 

THIS AMENDMENT NO. 5 TO LEASE (this “Amendment”) is made and entered into as of October 3, 2017 (the
“Effective Date”) between Landlord and Tenant named below: 
  

			
	 LANDLORD:
	  	 WE George Street, L.L.C.

		  	 c/o Winstanley Enterprises LLC

		  	 150 Baker Avenue Extension, Suite 303

		  	 Concord, MA 01742

		  	
	 TENANT:
	  	 Achillion Pharmaceuticals, Inc.

		  	 300 George Street

		  	 New Haven, CT 06510

		  	
	 BUILDING:
	  	 300 George Street

		  	New Haven, CT 06510

 WHEREAS, Landlord and Tenant executed a lease dated as of May 5, 2000 (as amended, the
“Suite 800 Lease”) by which Tenant leases approximately 20,148 rentable square feet on the 8th floor of the Building known as Suite 800 (“Suite 800”); and 

WHEREAS, Landlord and Tenant executed letters dated May 5, 2000, July 21, 2000, August 7, 2000 and December 22,
2000 regarding the initial alterations, the amount of the security deposit and provision of a letter of credit in lieu of a cash security deposit under the Suite 800 Lease; and 

WHEREAS, Landlord and Tenant executed an Amendment No. 1 to Lease dated as of February 1, 2001 whereunder the parties amended
the Suite 800 Lease to add approximately 200 rentable square feet of space on the first floor of the Building known as Suite CS02 (“Suite CS02”) and approximately 446 rentable square feet of space in the basement of the Building
known as Suite NMRl (“NMR1”); and 
 WHEREAS, Landlord and Tenant executed a lease dated as of March 6, 2002
(as amended, the “Lease”) by which Tenant leases approximately 8,768 rentable square feet on the second floor of the Building (“Initial Suite 202”); and 

WHEREAS, Landlord and Tenant executed an Amendment No. 1 to Lease dated as of September 10, 2002 whereunder the parties added
approximately 2,293 rentable square feet of space on the second floor of the Building to Initial Suite 202 such that Tenant leases a total of approximately 11,061 rentable square feet of space on the second floor, and all of which is known as Suite
202 (“Suite 202”); and 
 WHEREAS, Landlord and Tenant executed an Amendment No. 2 to Lease dated as of
March 31, 2010 whereunder the parties (i) terminated the Suite 800 Lease and revised the Premises to include all of the space leased by Tenant in the Building consisting of Suite 202, Suite 800, Suite CS02, and Suite NMR1, comprising the
Premises to be 31,800 square feet in the aggregate, and (ii) extended the Term of the Lease through March 31, 2017, and (iii) made certain other modifications and corrections to the Lease; and 

  
 1 

 WHEREAS, Landlord and Tenant executed an Amendment No. 3 to Lease dated as of
August 20, 2015 that amended the Lease to add approximately 6,832 rentable square feet of space on the ground floor of the Building (“Ground Floor Expansion Premises”) and extended the Term of the Lease to March 31, 2020;
and 
 WHEREAS, Landlord and Tenant executed an Amendment No. 4 to Lease dated as of April 7, 2016 that amended the Lease
to add approximately 2,877 rentable square feet of space on the ground floor of the Building (“Suite G5 Space”); and 

WHEREAS, Tenant desires to install an exterior sign on the Building, on the terms and conditions set forth below. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant
hereby agree as follows: 
 1. Capitalized terms used but not defined herein shall have the meaning ascribed to each in the Lease. 

2. Commencing as of the Effective Date and continuing only for so long as Tenant (and not any subtenant, assignee or successor) is operating
in the Premises, Tenant, but not any subtenant, assignee or successor of Tenant (these rights being personal to Tenant), shall have the exclusive right, at its sole cost and expense, to install an exterior sign on the southeast corner of the
Building in the format shown on Exhibit A attached hereto and made part hereof, which signage shall display Tenant’s tradename and corporate logo (collectively, the “Signage”). The type and design of such Signage
shall be subject to the prior written approval of Landlord and Tenant shall permit and maintain the Signage in compliance with applicable governmental rules and regulations governing such signs. Tenant shall be responsible to Landlord for any damage
caused by installation, use, or maintenance of said Signage and for any and all costs incurred in connection with obtaining and maintaining any required sign permit or approval. Tenant shall remove the Signage and restore the area occupied by the
Signage prior to the Termination Date, and Tenant shall be solely responsible and liable for the repair and damage caused by such removal and the restoration of all affected areas at its sole cost and expense prior to such Termination Date.
Notwithstanding anything to the contrary contained in the Lease or this Amendment, Landlord from time to time (i) shall have the right to temporarily obstruct the visibility of, or temporarily remove the Signage if reasonably required in
connection with the maintenance or repair of the Building, but in the event the obstruction or removal extends past seven (7) days in connection with a maintenance or repair project, there shall be an abatement of the Signage Fee (as defined
below) until the Signage becomes unobstructed or is re-mounted and/or (ii) shall have the right to remove and relocate the Signage if reasonably required in connection with any addition or improvement to
the Building to a mutually agreed new location; provided, however, if the parties cannot agree to a new location Tenant shall have the option of (i) accepting the location proposed by Landlord, or (ii) relinquishing its right to have the
Signage on the Building, in which case Tenant shall no longer be obligated to pay the Signage Fee. 

  
 2 

 3. From and after the Effective Date, Tenant shall, at its sole cost and expense, perform all
maintenance and repair of the Signage. If Tenant fails to make any necessary repairs of the Signage within fifteen (15) days after notice from Landlord, or such other reasonable time given the nature and urgency of the repair (although notice
from Landlord shall be required if there is an emergency), Landlord may make the repairs, and Tenant shall pay the reasonable cost of the repairs to Landlord within thirty (30) days after receipt of an invoice. 

4. Commencing on the earlier of (i) the date on which the Signage is installed (subject to written approval of Landlord) and begins to
draw power or (ii) December 1, 2017 (the “Signage Commencement Date”), Tenant agrees to pay each year for the remainder of the Term an annual fee of $7,500.00, payable in monthly installments of $625.00 (the
“Signage Fee”) for the signage rights described herein. The Signage Fee shall be due and payable in advance on the first day of each calendar month without notice or demand. 

5. Tenant shall commence paying for all utilities separately metered, submetered or allocated to the Signage as of the Signage Commencement
Date. 
 6. Landlord and Tenant represent and warrant to the other that each has full authority to enter into this Amendment and further
agree to hold harmless, defend, and indemnify the other from any loss, costs (including reasonable attorneys’ fees), damages, or claim arising from any lack of such authority. 

7. As modified herein, the Lease is hereby ratified and confirmed and shall remain in full force and effect. 

8. Landlord and Tenant hereby represent and warrant to the other that each has not dealt with any broker, finder or like agent in connection
with this Amendment and each does hereby agree to indemnify and hold the other, its agents and their officers, directors, shareholders, members, partners and employees, harmless of and from any claim of, or liability to, any broker, finder or like
agent claiming a commission or fee by reason of having dealt with either party in connection with the negotiation, execution or delivery of this Amendment, and all expenses related thereto, including, without limitation, reasonable attorneys’
fees and disbursements. 
 9. This Amendment constitutes the entire agreement by and between the parties hereto and supersedes any and all
previous agreements, written or oral, between the parties. No modification or amendment of this Amendment shall be effective unless the same shall be in writing and signed by the parties hereto. The provisions of this Amendment shall inure to the
benefit of, and be binding upon, the parties hereto and their respective legal representatives, successors and assigns. 
 10. This
Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of such counterparts shall constitute one agreement. This Amendment shall become effective when duly executed and delivered by all
parties hereto. 
 (Signatures on following page) 

  
 3 

 IN WITNESS WHEREOF, Landlord and Tenant have signed this Amendment No. 5 to Lease as
of the day and year first above written. 
  

							
	 LANDLORD:
  

WE GEORGE STREET, L.L.C.,
 a Delaware limited liability
company

		
	By:	 	 WE George Street Holding LLC,
 a
Delaware limited liability company,
 Its Member

			
		 	By:	 	 VTR LS-George Member LLC,

a Delaware limited liability company,
 Its Managing
Member

				
		 		 	By:	 	 /s/ Carter J. Winstanley
 Name: Carter J.
Winstanley
 Title:   Authorized Signatory

  

			
	 TENANT:
  

ACHILLION PHARMACEUTICALS, INC.

		
	By:	 	/s/ Mary Kay Fenton
		 	 Name: Mary Kay Fenton

Title:   Chief Financial Officer

  
 4 

 EXHIBIT A 

SIGNAGE 
  

 
  
 

 

  
 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]